Sammanfattning
Abstract
The levo-isomers of certain imidazole derivatives, particularly medetomidine, have been found to be inverse agonists of adrenergic ଱-2 receptors and are therefore useful in the prevention or treatment of conditions associated with overexpression or hypersensitization of the adrenergic ଱-2 receptors, such as obesity, a withdrawal symptom to an adrenergic ଱-2 receptor agonist, a neurological disorder, multiple system atrophy, diabetes mellitus, benign prostatic hyperplasia, and drug-induced sensitization of adrenergic ଱-2 receptors. The pharmaceutical composition is preferably transdermal.
The levo-isomers of certain imidazole derivatives, particularly medetomidine, have been found to be inverse agonists of adrenergic ଱-2 receptors and are therefore useful in the prevention or treatment of conditions associated with overexpression or hypersensitization of the adrenergic ଱-2 receptors, such as obesity, a withdrawal symptom to an adrenergic ଱-2 receptor agonist, a neurological disorder, multiple system atrophy, diabetes mellitus, benign prostatic hyperplasia, and drug-induced sensitization of adrenergic ଱-2 receptors. The pharmaceutical composition is preferably transdermal.
| Originalspråk | engelska |
|---|---|
| Utgivningsår | 30 nov 1999 |
| Status | Publicerad - 30 nov 1999 |
| MoE-publikationstyp | H1 Beviljat patent |